Genprex (GNPX) Competitors $1.10 -0.18 (-14.06%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends GNPX vs. AYTU, IPA, NKGN, INDP, TSBX, PHXM, KPRX, TRIB, MBIO, and IMNNShould you be buying Genprex stock or one of its competitors? The main competitors of Genprex include Aytu BioPharma (AYTU), ImmunoPrecise Antibodies (IPA), NKGen Biotech (NKGN), Indaptus Therapeutics (INDP), Turnstone Biologics (TSBX), PHAXIAM Therapeutics (PHXM), Kiora Pharmaceuticals (KPRX), Trinity Biotech (TRIB), Mustang Bio (MBIO), and Imunon (IMNN). These companies are all part of the "pharmaceutical products" industry. Genprex vs. Aytu BioPharma ImmunoPrecise Antibodies NKGen Biotech Indaptus Therapeutics Turnstone Biologics PHAXIAM Therapeutics Kiora Pharmaceuticals Trinity Biotech Mustang Bio Imunon Genprex (NASDAQ:GNPX) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment. Does the MarketBeat Community prefer GNPX or AYTU? Aytu BioPharma received 56 more outperform votes than Genprex when rated by MarketBeat users. Likewise, 67.11% of users gave Aytu BioPharma an outperform vote while only 65.25% of users gave Genprex an outperform vote. CompanyUnderperformOutperformGenprexOutperform Votes19965.25% Underperform Votes10634.75% Aytu BioPharmaOutperform Votes25567.11% Underperform Votes12532.89% Which has better earnings & valuation, GNPX or AYTU? Aytu BioPharma has higher revenue and earnings than Genprex. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenprexN/AN/A-$30.86MN/AN/AAytu BioPharma$81M0.11-$15.84M-$1.23-1.21 Which has more volatility and risk, GNPX or AYTU? Genprex has a beta of -1.3, suggesting that its stock price is 230% less volatile than the S&P 500. Comparatively, Aytu BioPharma has a beta of -1.4, suggesting that its stock price is 240% less volatile than the S&P 500. Do institutionals and insiders hold more shares of GNPX or AYTU? 14.1% of Genprex shares are owned by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are owned by institutional investors. 8.5% of Genprex shares are owned by insiders. Comparatively, 2.8% of Aytu BioPharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is GNPX or AYTU more profitable? Genprex has a net margin of 0.00% compared to Aytu BioPharma's net margin of -8.28%. Aytu BioPharma's return on equity of -21.89% beat Genprex's return on equity.Company Net Margins Return on Equity Return on Assets GenprexN/A -409.48% -269.17% Aytu BioPharma -8.28%-21.89%-5.37% Do analysts rate GNPX or AYTU? Genprex currently has a consensus price target of $10.00, suggesting a potential upside of 809.09%. Given Genprex's stronger consensus rating and higher probable upside, analysts clearly believe Genprex is more favorable than Aytu BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genprex 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Aytu BioPharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor GNPX or AYTU? In the previous week, Aytu BioPharma had 4 more articles in the media than Genprex. MarketBeat recorded 7 mentions for Aytu BioPharma and 3 mentions for Genprex. Genprex's average media sentiment score of 1.50 beat Aytu BioPharma's score of 0.51 indicating that Genprex is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genprex 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Aytu BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAytu BioPharma beats Genprex on 8 of the 15 factors compared between the two stocks. Ad Wide Moat ResearchTrump said you could learn something from this manEarly Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide victory. Yet one former Trump advisor says the picture is less rosy than it seems. “I’ve found a deep crack forming in the foundations of the US economy,” he says. “And before too long, it could tear our country apart.” It’s critical you learn more today, BEFORE it impacts your money and your retirement. Here’s everything you need to know. Get Genprex News Delivered to You Automatically Sign up to receive the latest news and ratings for GNPX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNPX vs. The Competition Export to ExcelMetricGenprexPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.85M$6.43B$5.04B$8.82BDividend YieldN/A8.11%5.17%4.07%P/E RatioN/A10.10122.4217.58Price / SalesN/A243.351,179.2973.96Price / CashN/A22.1633.5632.51Price / Book0.225.474.694.68Net Income-$30.86M$153.61M$118.98M$225.87M7 Day Performance-31.25%-4.33%-2.45%-2.03%1 Month Performance166.34%-8.62%-4.03%0.07%1 Year Performance-89.40%28.78%29.80%24.55% Genprex Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNPXGenprex4.334 of 5 stars$1.10-14.1%$10.00+809.1%-89.4%$2.85MN/A0.0020News CoveragePositive NewsGap UpAYTUAytu BioPharma1.3142 of 5 stars$1.49-6.9%N/A-37.9%$9.16M$81M-1.30160IPAImmunoPrecise Antibodies2.0175 of 5 stars$0.39-4.9%$6.00+1,454.8%-72.2%$11.13M$24.09M-0.4980NKGNNKGen BiotechN/A$0.31+6.8%N/A-89.1%$11.07M$80,000.00-0.06N/AINDPIndaptus Therapeutics3.0922 of 5 stars$1.07+3.9%$8.50+694.4%-48.7%$10.91MN/A-0.636TSBXTurnstone Biologics3.4396 of 5 stars$0.46-2.1%$2.13+362.1%-84.8%$10.89M$19.31M0.0082PHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049KPRXKiora Pharmaceuticals2.9938 of 5 stars$3.42+5.9%$10.00+192.4%-32.4%$10.26M$16M0.0010TRIBTrinity Biotech1.8036 of 5 stars$1.30-1.5%N/A-33.5%$10.06M$56.83M0.00480Gap DownMBIOMustang Bio1.9365 of 5 stars$0.21-4.6%$2.00+856.9%-87.6%$9.99MN/A-0.14100IMNNImunon3.0809 of 5 stars$0.68-1.4%$12.00+1,654.4%-26.5%$9.92M$500,000.00-0.3633 Related Companies and Tools Related Companies AYTU Competitors IPA Competitors NKGN Competitors INDP Competitors TSBX Competitors PHXM Competitors KPRX Competitors TRIB Competitors MBIO Competitors IMNN Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GNPX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genprex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genprex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
